Short description
MannKind focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes.
Description
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA(R), is in the late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. It maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind.
Last funding
Noaccessforu
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Valencia, California, United States, North America
Founded on
January 1, 2001
Exited on
August 6, 2004
Went public on
August 6, 2004
Stock symbol
MNKD
Non-profit?
No
Acquired?
No
Employees count
501-1000
Revenue range
$7890 - 12340
Sign in for full access
Investors
Blurry Noaccess, Noaccess
Sign in for full access
Founders
Alfred E. Mann